Company Information

  

Address: PAASHEUVELWEG 25A  
City: AMSTERDAM 
State:  
Zip Code: 1105 BP 
Telephone: 1-339-970-7000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a leader in the field of gene therapy, seeking to develop single treatments with potentially curative results for patients suffering from genetic and other devastating diseases. We are advancing a focused pipeline of innovative gene therapies that have been developed both internally and through partnerships, such as our collaboration with Bristol Myers-Squibb focused on cardiovascular diseases. We have established clinical proof-of-concept in our lead indication, hemophilia B and achieved preclinical proof-of-concept in Huntington's disease. We believe our validated technology platform and manufacturing capabilities provide us distinct competitive advantages, including the potential to reduce development risk, cost and time to market. We produce our AAV-based gene therapies in our own facilities with a proprietary, commercial-scale, consistent, manufacturing process.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-2.61NAN/E
06/2017-2.82NAN/E
03/2017-2.83NAN/E
12/2016-2.93NAN/E
12/2015-3.24NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.67
Net Inc/Total Assets-0.39Total Liab/Inv Cap0.76
Net Inc/Inv Cap-0.44Total Liab/Comm Equity0.27
Pretax Inc/Net Sales-2.88Interest Coverage Ratio-32.25
Net Inc/Net Sales-2.92Curr Debt/Equity0.01
Cash Flow/Net Sales-2.88LTD/Equity0.31
SG&A/NetSales0.98Total Debt/Equity0.32
Asset Utilization   Liquidity  
Net Receivables Turnover3.77Quick Ratio6.34
Inventory TurnoverNACurrent Ratio6.34
Inventory Day SalesNANet Rec/Curr Assets0.06
Net Sales/Work Cap0.21Inv/Curr AssetsNA
Net Sales/PP&E0.70  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2013
Total Revenues(Net Sales) 2.26 4.94 3.32 1.28
Cost of Goods Sold NA NA NA 0.02
Selling & Admin Exps -8.57 7.78 6.04 6.10
Operating Income -9.28 -19.71 -19.72 -9.66
Interest Exp 0.58 0.50 0.50 -0.29
Pretax Income -10.52 -21.27 -20.27 -9.31
Other Income -0.67 -1.06 -0.05 0.08
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -10.25 -21.27 -20.27 -9.31

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2013
Cash & Short Term Investments 88.93 104.09 120.27 32.81
Receivables - Total 1.95 5.82 1.75 4.11
Inventories - Total NA NA NA 1.19
Total Current Assets 92.32 111.43 123.73 38.11
Net Property, Plant & Equipment 34.65 35.41 35.24 3.60
Total Assets 138.99 157.97 169.64 53.70
Liabilities        
Accounts Payable 13.15 12.90 11.11 10.47
Debt in Current Liabilities 6.23 4.32 2.44 2.17
Total Current Liabilities 25.37 23.13 20.47 14.40
Long-Term Debt 14.35 16.15 17.92 8.67
Total Liabilities 119.38 130.68 123.91 46.03
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 1.61 1.61 1.60 0.84
Retained Earnings -447.84 -437.60 -416.33 -198.48
Treasury Stock NA NA NA NA
Total Stockholders' Equity 19.61 27.29 45.73 7.67
Total Liabilities and Stockholders' Equity 138.99 157.97 169.64 53.70

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2013
Net Cash Provided by Operating Activities -15.42 -19.13 -11.67 -7.97
Net Cash Provided by Investing Activities -1.53 -1.44 -1.97 -2.57
Net Cash Provided by Financing Activities 0.10 0.50 0.44 0.79

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-19.40--
12/20134.06-36.96--
12/20146.14-49.78--
12/201510.58-82.08-3.24
12/201625.10-73.37-2.93
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17427,73625.12




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.